Drug Type CAR-T |
Synonyms Mesothelin CAR-T cell therapy(Novartis Pharma), NIU-440 |
Target |
Action modulators |
Mechanism MSLN modulators(Mesothelin modulators), T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Malignant Pleural Mesothelioma | Phase 1 | United States | 01 Jun 2014 | |
Mesothelin positive Neoplasms | Phase 1 | United States | 01 Jun 2014 | |
Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 | United States | 01 Jun 2014 | |
Ovarian Serous Tumor | Phase 1 | United States | 01 Jun 2014 | |
Pancreatic adenocarcinoma metastatic | Phase 1 | United States | 01 Jun 2014 | |
Mesothelioma | Phase 1 | - | - | |
Ovarian Cancer | Phase 1 | - | - | |
Pancreatic Cancer | Phase 1 | - | - |